Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071858 | 0.76 | CYP1A2 (0.46) | CYP2A6 | |
| SCHEMBL4358400 | 0.74 | METAP2 (0.31) | — | |
| SCHEMBL16049760 | 0.74 | — | — | |
| SCHEMBL3282411 | 0.74 | NCF1 (0.45) | — | |
| SCHEMBL4851470 | 0.74 | CYP3A4 (0.30) | — | |
| SCHEMBL3956168 | 0.74 | KDM4E (0.35) | CYP2A6 | |
| SCHEMBL4842462 | 0.74 | NCF1 (0.52) | — | |
| SCHEMBL17784064 | 0.70 | CYP1A2 (0.50) | — | |
| SCHEMBL3950907 | 0.69 | SOS2 (0.44) | — | |
| SCHEMBL16720148 | 0.69 | RAB9A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER. INC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | HTR2C, HTR2A, HTR5A | CYP2A6 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.